President Trump announced landmark drug pricing agreements with nine pharmaceutical companies and the launch of TrumpRx.gov, ...

The companies agreed to sell most of their drugs to Medicaid at the prices they charge in European countries and to sell ...

Attorney General Jason Miyares today filed a lawsuit against the nation’s largest pharmacy benefit managers and insulin manufacturers in the Circuit Court for ...

Virginia is accusing some of the largest names in the prescription drug industry of artificially inflating the prices of insulin, a life-saving medication, over the course of several years.

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S.

Charlotte officials claimed in the lawsuit that insulin, which costs about $2 to produce, can be sold by manufacturers for as much as $700.

Nine drug manufacturers will offer their drugs to Medicaid recipients at most-favored-nation discounts in exchange for tariff ...

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.